Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?
作者信息
Costa D B, Kobayashi S
出版信息
Br J Cancer. 2007 Jan 29;96(2):399; author reply 400. doi: 10.1038/sj.bjc.6603564. Epub 2007 Jan 16.
Abstract
摘要
相似文献
1
Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?
Br J Cancer. 2007 Jan 29;96(2):399; author reply 400. doi: 10.1038/sj.bjc.6603564. Epub 2007 Jan 16.
2
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44. doi: 10.1158/1078-0432.CCR-05-1846.
3
Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
J Clin Pathol. 2011 Nov;64(11):947-52. doi: 10.1136/jclinpath-2011-200169. Epub 2011 Jul 1.
4
Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
Eur J Clin Pharmacol. 2016 Jan;72(1):1-11. doi: 10.1007/s00228-015-1966-0.
5
Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
Cancer Chemother Pharmacol. 2017 May;79(5):1013-1020. doi: 10.1007/s00280-017-3285-x. Epub 2017 Apr 8.
6
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.
Lung Cancer. 2015 Feb;87(2):148-54. doi: 10.1016/j.lungcan.2014.11.013. Epub 2014 Nov 29.
7
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Clin Cancer Res. 2006 Jul 1;12(13):3908-14. doi: 10.1158/1078-0432.CCR-06-0462.
8
Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation.
Oncology. 2014;87(4):215-23. doi: 10.1159/000362603. Epub 2014 Jul 15.
9
Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
Lung Cancer. 2006 Jul;53(1):117-21. doi: 10.1016/j.lungcan.2006.04.008. Epub 2006 May 30.
10
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.
Lancet Oncol. 2012 Jan;13(1):e23-31. doi: 10.1016/S1470-2045(11)70129-2. Epub 2011 Jul 19.
引用本文的文献
1
Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib.
Med Oncol. 2014 Oct;31(10):203. doi: 10.1007/s12032-014-0203-5. Epub 2014 Sep 6.
2
microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation.
Med Oncol. 2013 Dec;30(4):750. doi: 10.1007/s12032-013-0750-1. Epub 2013 Nov 6.
3
[Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
Zhongguo Fei Ai Za Zhi. 2013 Mar;16(3):138-43. doi: 10.3779/j.issn.1009-3419.2013.03.04.
4
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.
Lung Cancer. 2007 Oct;58(1):95-103. doi: 10.1016/j.lungcan.2007.05.017. Epub 2007 Jul 3.
本文引用的文献
1
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
Br J Cancer. 2006 Oct 23;95(8):998-1004. doi: 10.1038/sj.bjc.6603393.
2
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Clin Cancer Res. 2006 Jul 1;12(13):3908-14. doi: 10.1158/1078-0432.CCR-06-0462.
3
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
J Clin Oncol. 2006 Jul 20;24(21):3340-6. doi: 10.1200/JCO.2005.05.4692. Epub 2006 Jun 19.
4
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44. doi: 10.1158/1078-0432.CCR-05-1846.
Zotero 插件